内外协同 锚定多肽产业新未来——专访翰宇药业双执行总裁唐洋明、沈亚平

Core Insights - The peptide drug sector is rapidly growing, with a projected global market size of $210.8 billion by 2030, driven by high activity, low toxicity, and strong targeting capabilities [1] - The company Hanyu Pharmaceutical has implemented a dual CEO management model to enhance collaboration and efficiency in drug development and market conversion [2][3] Industry Trends - The peptide drug industry, particularly in the GLP-1 segment, is experiencing a golden growth period with increasing competition [4] - Companies are focusing on differentiating their products through innovative drug design and effective market strategies to avoid homogenization [4][5] Company Strategy - Hanyu Pharmaceutical aims to build a competitive edge through a comprehensive industry chain, innovative research and development, and international quality standards [5] - The company has established a differentiated advantage in the GLP-1 pipeline by offering various dosage forms and maintaining low production costs [5] Future Outlook - Hanyu Pharmaceutical plans to leverage three strategic cards: enhancing international sales, preemptively positioning for expiring patents, and extending into innovative drug and technology platforms [7][8] - The company is focusing on long-term growth by addressing unmet clinical needs and exploring the small nucleic acid drug sector, which is expected to be a key growth area in the next 1 to 3 years [8]